Therapies Targeting LRRK2 Gene Could Benefit Broad Population of Parkinson’s Patients, Study Finds

The LRRK2 gene may play an important role in nonhereditary Parkinson’s disease, not just the familial form as previously thought, researchers at the University of Pittsburgh School of Medicine​ have discovered. “This discovery is extremely consequential for Parkinson’s disease because it suggests that therapies currently being developed for a small group of patients may benefit everybody

Beat It! Learning to Walk to Music Reduces Falls for Parkinson’s Patients

A training program in which patients walk while listening to regular beats can improve the velocity and cadence of Parkinson’s disease patients, while reducing their risk of falling, a study shows. The study, “Rhythmic auditory stimulation for reduction of falls in Parkinson’s disease: a randomized controlled study,” was published in the journal Clinical Rehabilitation. Parkinson’s disease patients

People with Reduced Smell, Taste Abilities at Risk of Parkinson’s Detected by Machine Learning

Machine learning identifies individuals with reduced odor and taste sensitivity as people at risk for developing Parkinson’s disease, researchers from Italy report. The approach could be part of a noninvasive method to study early-onset Parkinson’s, the findings suggest. The study, “Comparative Motor Pre-clinical Assessment in Parkinson’s Disease Using Supervised Machine Learning Approaches,” appeared in the

Chinese Compound Helps Reduce Levodopa-induced Dyskinesia, Eases Motor Symptoms in Parkinson’s, Study Finds

The traditional Chinese compound Zishenpingchan can be used as an add-on treatment to levodopa for improvements in motor symptoms and quality of life in patients with Parkinson’s disease, according to researchers. The study, “Zishenpingchan granules for the treatment of Parkinson’s disease: a randomized, double-blind, placebo-controlled clinical trial,” was published in the journal Neural Regeneration Research.

Common Anti-inflammatory Medication May Help Prevent Parkinson’s Neurodegeneration, Study Suggests

A type of immune cell called Th17 may be a key a promoter of neurodegeneration in Parkinson’s disease by producing the pro-inflammatory molecule interleukin-17 (IL-17), according to a study. Researchers also found that the common anti-inflammatory medication Cosentyx (secukinumab), an antibody against IL-17, seems to prevent this mechanism and the death of nerve cells. The study, “Th17

Cell Surface Molecule Seen as Player in Spread of Protein Clumps That Compose Lewy Bodies

How cell surface proteins participate in spreading, from one cell to another, misfolded proteins related to neurodegenerative diseases like Parkinson’s and Alzheimer’s, possibly aiding in the progression of these disorders, was seen in early research. The study, “Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates,”

Ketamine Studied for Relief of Levodopa-associated Involuntary Movements

A Phase 1 trial will test the potential of ketamine — an analgesic medicine used for depression and pain — at reducing the uncontrollable, jerky movements that arise in Parkinson’s disease patients after long-term treatment with levopoda. Levodopa, probably the most common treatment for Parkinson’s disease, is effective at improving the stiffness and slowness of movement that characterize the